Navigation Links
Two Phase III clinical trials on corifollitropin alfa (Org 36286),reach randomization target

ropin alfa, and is expected to complete recruitment on target by mid-August 2007.

About corifollitropin alfa
• Corifollitropin alfa is a new biological entity (NBE) and is being developed for controlled ovarian stimulation to induce the development of multiple follicles in patients participating in an assisted reproductive technology program.
• Corifollitropin alfa is the first compound in a new class of long-acting fertility hormones called ‘Sustained Follicle Stimulants’ (SFS). The primary advantage of an SFS over current gonadotropins is the longer duration of action which allows a treatment regimen replacing 7 daily injections of current gonadotropins with one injection of corifollitropin alfa.
• The LIFE program is Organon’s clinical development program for corifollitropin alfa for the therapeutic indication of controlled ovarian stimulation. The most important trials in this program are studies with the names ENGAGE (phase III efficacy and safety study with corifollitropin alfa 150 mcg), ENSURE (phase III efficacy and safety study in women =60 kg with corifollitropin alfa 100 mcg) and TRUST (phase III safety study on repeated treatment).


For media inquiries
Elina Daamen

N.V. Organon (Media Relations)
Visiting address: Molenstraat 110
5342 CC Oss
The Netherlands
Mailing address:

Elina Daamen, media relations

NV Organon






Page: 1 2 3

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:12/22/2014)...  Mark Farrah Associates (MFA), www.markfarrah.com , ... the 2015 marketplace exchange projections and insights about ... According to a recent ASPE (Office of the ... Health and Human Services) report, an estimated 6.7 ... through the Marketplace as of October 2014 and ...
(Date:12/22/2014)... Dec. 22, 2014 TWi Biotechnology, Inc., ... Allowance for AC-201, TWi Biotechnology,s lead drug candidate, ... China for patent application numbered ... acceptable salts, active metabolite for treatment of type ... of treatment using AC-201 for type II diabetes, ...
(Date:12/19/2014)... 2014 You,re visiting the dentist for what ... he or she says you need a root canal. ... may have several questions and feel apprehensive about your ... it,s nothing to worry about. The Pennsylvania Dental Association ... any anxiety the public may have surrounding this common ...
Breaking Medicine Technology:Insights into the Marketplace and Individual Market Growth 2TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 2TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 3Root Canals Have Become More Routine 2
... Inc. announced today that it has entered into ... to provide Otsuka with access to BioWa,s POTELLIGENT® ... of their antibody therapeutics with enhanced antibody-dependent cellular ... License was initiated in May, 2007 with Takeda ...
... PEAK Surgical, Inc. and Medtronic, Inc. (NYSE: MDT ... Technologies business at Medtronic exclusive rights for global distribution ... Adenoid) tissue dissection device for the ear, nose, and ... is a major step toward our goal of capturing ...
Cached Medicine Technology:BioWa Announces Second Japanese License of POTELLIGENT(R) Technology to Otsuka Pharmaceutical 2PEAK Surgical and Medtronic Announce Global Distribution Agreement for the Ear, Nose, and Throat Market 2PEAK Surgical and Medtronic Announce Global Distribution Agreement for the Ear, Nose, and Throat Market 3
(Date:12/22/2014)... December 22, 2014 Fad diets ... The reason why most fad diets have hung around ... problem with fad diets is that, as the body becomes ... dieter uncertain of how to reset the metabolism to return ... Diet Doc developed their all-inclusive diet plans that ...
(Date:12/22/2014)... 2014 On December 22, 2014, My ... Gordon Cashwell for an episode to celebrate Christmas. At ... is it so important to you that we all ... “We all should respect who Jesus was. I think ... Christian beliefs. That means that on Jesus’ birthday we ...
(Date:12/22/2014)... 21, 2014 (HealthDay News) -- A new vaccine created ... in deer might also protect livestock and even humans ... appears to help prevent deer from becoming infected by ... according to the report in the Dec. 21 online ... disease is caused by mysterious infectious particles known as ...
(Date:12/22/2014)... December 22, 2014 Explorys, the leader ... to its leadership team: Greg Yarrington as Vice President ... and Patrick Wells as Vice President of Solutions. These ... 80 new jobs in 2015 to support client demand ... its platform-as-a-service offerings, and growth of its partner network. ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 The MedTech industry ... Inc, a wholly owned subsidiary of PartnerTech AB of Sweden, ... having recently achieved additional ISO Certification. , All signs point ... employment and the likelihood of a repeal of the excise ... . The industry is anticipating annual growth of 9.3% and ...
Breaking Medicine News(10 mins):Health News:Diet Doc Announces the Difference Between Fad Diets and Real Weight Loss Programs to Help Dieters Make the Best Choice 2Health News:Diet Doc Announces the Difference Between Fad Diets and Real Weight Loss Programs to Help Dieters Make the Best Choice 3Health News:Diet Doc Announces the Difference Between Fad Diets and Real Weight Loss Programs to Help Dieters Make the Best Choice 4Health News:My Positive Perspective Celebrates Christmas With an Event to Celebrate the Birthday of Jesus 2Health News:Vaccine for Deer Against 'Mad Cow'-Like Illness Shows Promise 2Health News:Explorys Continues to Experience Rapid Growth, Adds Three Healthcare IT Executives to Its Leadership Team 2Health News:Explorys Continues to Experience Rapid Growth, Adds Three Healthcare IT Executives to Its Leadership Team 3Health News:PartnerTech Inc. Poised for Growth in MedTech 2
... eggs to deteriorate in quality with age, and can that ... egg -- out of a stash of roughly one million ... be influenced to pick a "good" quality egg rather than ... much on the mind of fertility researcher Teresa Woodruff. Woodruff, ...
... a key protein might reap rewards for people ... (HealthDay News) -- Researchers have uncovered cellular proteins that ... according to a new study. , The findings, ... new treatments for a range of human diseases that ...
... WASHINGTON, June 19 Most seniors -,regardless ... Medicare or Medicare,Advantage - oppose cutting the ... payment fix and believe cuts to Medicare ... a new survey finds., Power Point ...
... Protections for Poor Beneficiaries, SAN FRANCISCO, June ... federal court today in the Medicare Part D ... has agreed to make,significant changes to its administration ... approved by the judge, the agreement will,make it ...
... DALLAS, June 19 Federal Reserve chairman Ben Bernanke,s,comments ... health care,system is one of the biggest challenges facing ... care costs will rise nearly 10 percent this,year, lend ... emphasis on,prevention and wellness, according to U.S. Preventive Medicine, ...
... Better Health offers members access to 75 generic drugs at no cost ... ... Independence Blue Cross (IBC),will waive copays and coinsurance on 75 generic drugs ... a member incentive,program designed to help our members become more actively involved ...
Cached Medicine News:Health News:New photo 'op' for ovaries may solve some mysteries of infertility 2Health News:Autoimmune Disease Treatment May Not Dampen Immune System 2Health News:Autoimmune Disease Treatment May Not Dampen Immune System 3Health News:Autoimmune Disease Treatment May Not Dampen Immune System 4Health News:Seniors Oppose Cutting Medicare Advantage to Fund Physician Payment Fix 2Health News:Bush Administration Settles Nationwide Class Action in Medicare Prescription Drug Case 2Health News:Bush Administration Settles Nationwide Class Action in Medicare Prescription Drug Case 3Health News:U.S. Preventive Medicine Views Bernanke's Comments as Strong Support for Prevention and Wellness Programs 2Health News:Independence Blue Cross Waives Copays for Generics Used to Treat Certain Chronic Conditions 2Health News:Independence Blue Cross Waives Copays for Generics Used to Treat Certain Chronic Conditions 3Health News:Independence Blue Cross Waives Copays for Generics Used to Treat Certain Chronic Conditions 4
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: